The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...

iOnctura has begun a randomized phase 1/2 study investigating its lead asset, roginolisib, in combination with dostarlimab, ...

Janssen-Cilag International NV, a Johnson & Johnson company, has submitted an application to the European Medicines Agency ...

The Americas Awards are excited to introduce a new category, Clinical Trial Administrator. This category is designed to ...

Chiesi UK and Ireland and Wirral Primary Care Collaborative (WPCC) have launched COMET, a programme designed to enhance early ...

UCB has announced that its developmental treatment DoxTM, a combination of doxecitine and doxribtimine, has been granted ...

Groundbreaking research has identified over 900 genetic links to osteoarthritis, including 500 previously undiscovered, in a ...

NICE reviewed various technologies and recommended DERM as the only AI tool suitable for NHS use. It is the first dermatology ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza (teprotumumab) as the first licensed treatment for adults with ...